Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can 'Supercharged' donor cells beat viruses that drugs Can't?

NCT ID NCT07662369

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure how many patients clear the virus or see at least a 50% reduction in viral load.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CD45RA-depleted donor lymphocyte infusion (DLI)

What this could lead to

If it works, this could offer a new way to fight viral infections that don't respond to standard drugs after a stem cell transplant.

What could go wrong

This is an early phase 1/2 trial with only 30 participants, so results are preliminary. There may be risks like graft-versus-host disease or the treatment not working for all viruses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease BK-virus nephropathy cytomegalovirus infection Epstein-Barr virus infection erythema infectiosum hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm herpes simplex type 1 infectious disease herpes simplex type 2 infectious disease progressive multifocal leukoencephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAPLO-IDENTICAL HCT HEMATOLOGIC MALIGNANCY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital

    RECRUITING

    Shanghai, SH, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••